TerminatedNCT00270257
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
Medication studyAges 18+China + ThailandAddiction
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- Hengzhou Town and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateMay 2008
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 1,251
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- China, Thailand
- Age range
- Over 18 Years
- Official registry ID
- NCT00270257
- Official title
Show the full official title
A Phase III Randomized Controlled Trial to Evaluate the Efficacy of Drug Treatment in Prevention of HIV Infection and Death Among Opiate Dependent Injectors
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Hengzhou Town, China · Nanning, China · Ürümqi, China
1 more locations
- Chiang Mai, Thailand
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Allergy and Infectious Diseases (NIAID), a research institute.
Does this study involve medication?
Yes. The study involves medication, including Buprenorphine/Naloxone.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as terminated.
